---
title: "uniQure’s AMT-130 Gene Therapy Shows Promising Results in Huntington’s Disease Trials, Justifying Buy Rating and $70 Price Target"
description: "Patrick Trucchio has reiterated a Buy rating for uniQure, citing promising results from AMT-130's Phase 1/2 trials for Huntington’s disease, which showed significant slowing of disease progression and"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258734311.md"
published_at: "2025-09-24T14:45:20.000Z"
---

# uniQure’s AMT-130 Gene Therapy Shows Promising Results in Huntington’s Disease Trials, Justifying Buy Rating and $70 Price Target

> Patrick Trucchio has reiterated a Buy rating for uniQure, citing promising results from AMT-130's Phase 1/2 trials for Huntington’s disease, which showed significant slowing of disease progression and reduced neurodegeneration biomarkers. The successful primary endpoint and potential for a Biologics License Application in early 2026 enhance the positive outlook. With robust safety data over 36 months, Trucchio sets a $70 price target for uniQure's stock, supported by his strong track record in the Healthcare sector.

Patrick Trucchio has given his Buy rating due to a combination of factors including the promising results from uniQure’s pivotal Phase 1/2 clinical trials for AMT-130, a gene therapy candidate for Huntington’s disease. The trials demonstrated a significant slowing in disease progression and a reduction in neurodegeneration biomarkers, which positions AMT-130 as a leading candidate for addressing this serious condition with no current disease-modifying treatments.  
Furthermore, the successful meeting of the trial’s primary endpoint and the potential for a Biologics License Application filing in the first quarter of 2026, along with a possible accelerated approval, contribute to the positive outlook. The robust data, including safety and tolerability over 36 months, support the confidence in AMT-130’s potential, justifying the reiterated Buy rating and the $70 price target for uniQure’s stock.

According to TipRanks, Trucchio is a 5-star analyst with an average return of 15.2% and a 46.19% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as GH Research, Arrowhead Pharmaceuticals, and Oncolytics Biotech.

### Related Stocks

- [QURE.US - Uniqure](https://longbridge.com/en/quote/QURE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| uniQure updates gene therapy pipeline and regulatory outlook | uniQure N.V. has updated its gene therapy pipeline, emphasizing its leadership in the field with a strong clinical pipel | [Link](https://longbridge.com/en/news/272411626.md) |
| uniQure Announces Type A Meeting Scheduled with FDA \| QURE Stock News | uniQure N.V. has scheduled a Type A meeting with the FDA to discuss the Biologics License Application for AMT-130, a gen | [Link](https://longbridge.com/en/news/272072303.md) |
| Genflow Biosciences Reports Positive Interim Results for SIRT6 Gene Therapy in Aged Dogs | Genflow Biosciences plc has reported positive interim results from its SLAB clinical trial of SIRT6 gene therapy in aged | [Link](https://longbridge.com/en/news/275712514.md) |
| Alzheimer's Therapeutics Market to Reach USD 10.4 Billion by 2036 as Disease-Modifying Immunotherapies Transform Treatment Paradigms | The global Alzheimer's therapeutics market is projected to grow from USD 4.3 billion in 2026 to USD 10.4 billion by 2036 | [Link](https://longbridge.com/en/news/275776592.md) |
| 05:30 ETReal-World Evidence: Improved Pain and Function Scores Reported in Posterior Tibial Tendon Degeneration | Physicians from the University Foot & Ankle Institute and Regenative Labs published a peer-reviewed study on umbilical c | [Link](https://longbridge.com/en/news/275740095.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.